Supernus Pharmaceuticals, Inc. (LON: 0LB2)
London
· Delayed Price · Currency is GBP · Price in USD
38.43
+0.82 (2.17%)
Jan 21, 2025, 2:47 PM BST
Supernus Pharmaceuticals Employees
Supernus Pharmaceuticals had 652 employees as of December 30, 2023. The number of employees increased by 40 or 6.54% compared to the previous year.
Employees
652
Change (1Y)
40
Growth (1Y)
6.54%
Revenue / Employee
746.07K GBP
Profits / Employee
68.33K GBP
Market Cap
1.71B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
ConvaTec Group | 10,136 |
Hikma Pharmaceuticals | 9,100 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Supernus Pharmaceuticals News
- 5 weeks ago - Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada - GlobeNewsWire
- 2 months ago - Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth - Seeking Alpha
- 2 months ago - Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - GlobeNewsWire
- 3 months ago - Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder - GlobeNewsWire